GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » Shares Outstanding (Diluted Average)

Bio-Path Holdings (Bio-Path Holdings) Shares Outstanding (Diluted Average) : 0.65 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Bio-Path Holdings's average diluted shares outstanding for the quarter that ended in Mar. 2024 was 0.65 Mil.


Bio-Path Holdings Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Bio-Path Holdings's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings Shares Outstanding (Diluted Average) Chart

Bio-Path Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.19 0.34 0.36 0.48

Bio-Path Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.40 0.50 0.61 0.65

Bio-Path Holdings Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Bio-Path Holdings  (NAS:BPTH) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Bio-Path Holdings Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Path Holdings (Bio-Path Holdings) Business Description

Industry
Traded in Other Exchanges
Address
4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
Executives
Aline Sherwood director 347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen director 1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese director 4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen director, officer: President, CEO & CFO 20651 PRINCE CREEK, KATY TX 77450
Paul Aubert director 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver director 4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller officer: COO & Secretary 17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison director 2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris director 550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read director C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison director P O BOX 150248, OGDEN UT 84415

Bio-Path Holdings (Bio-Path Holdings) Headlines

From GuruFocus

Bio-Path Holdings Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-06-2022

Bio-Path Holdings Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-12-2023

Bio-Path Holdings Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 07-06-2022

Bio-Path Holdings Reports Third Quarter 2022 Financial Results

By Value_Insider Value_Insider 11-15-2022

Bio-Path Holdings Reports Full Year 2022 Financial Results

By sperokesalga sperokesalga 03-31-2023

Bio-Path Holdings Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-17-2022